Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$64.82 -0.3%	$61.00	$43.70 ▼ $86.53	$2.06B	-1.48	48,596 shs	14,155 shs
CGON CG Oncology	$26.79 +0.8%	$23.05	$14.80 ▼ $40.47	$2.04B	1.08	825,204 shs	530,440 shs
DNLI Denali Therapeutics	$13.93 -0.2%	$13.84	$10.57 ▼ $33.33	$2.02B	1.49	1.12 million shs	2.07 million shs
KURA Kura Oncology	$6.42 +1.9%	$6.08	$5.41 ▼ $23.48	$555.81M	0.5	1.21 million shs	1.60 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	-0.73%	+6.59%	+3.77%	+8.73%	+32.83%
CGON CG Oncology	+3.46%	+4.52%	-8.47%	+7.22%	-18.39%
DNLI Denali Therapeutics	+5.92%	+4.02%	-15.09%	-12.48%	-24.78%
KURA Kura Oncology	+10.92%	+11.70%	-2.63%	-14.05%	-69.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLTE Belite Bio	2.0069 of 5 stars	3.5	3.0	0.0	1.3	0.8	0.6
CGON CG Oncology	2.4666 of 5 stars	4.5	1.0	0.0	3.2	0.8	0.0
DNLI Denali Therapeutics	4.3629 of 5 stars	4.5	1.0	4.7	3.0	2.5	0.0
KURA Kura Oncology	4.4287 of 5 stars	4.5	2.0	4.7	3.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	3.00	Buy	$96.67	49.13% Upside
CGON CG Oncology	3.00	Buy	$58.22	117.33% Upside
DNLI Denali Therapeutics	3.06	Buy	$33.71	142.03% Upside
KURA Kura Oncology	2.93	Moderate Buy	$24.50	281.62% Upside

Current Analyst Ratings Breakdown

Latest KURA, DNLI, BLTE, and CGON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $52.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/19/2025	KURA Kura Oncology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/15/2025	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/15/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/7/2025	DNLI Denali Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $32.00
5/2/2025	CGON CG Oncology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$41.00
5/2/2025	KURA Kura Oncology	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $11.00
4/29/2025	CGON CG Oncology	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$66.00 ➝ $68.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$3.28 per share	N/A
CGON CG Oncology	$662K	3,084.69	N/A	N/A	($1.94) per share	-13.81
DNLI Denali Therapeutics	$330.53M	6.12	N/A	N/A	$7.42 per share	1.88
KURA Kura Oncology	$67.99M	8.17	N/A	N/A	$5.35 per share	1.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$31.63M	-$1.36	N/A	N/A	N/A	N/A	-31.94%	-30.73%	8/8/2025 (Estimated)
CGON CG Oncology	-$48.61M	-$1.51	N/A	N/A	N/A	-10,642.98%	-18.97%	-15.36%	8/14/2025 (Estimated)
DNLI Denali Therapeutics	-$145.22M	-$2.67	N/A	N/A	N/A	N/A	-32.94%	-30.04%	7/30/2025 (Estimated)
KURA Kura Oncology	-$152.63M	-$2.10	N/A	N/A	N/A	N/A	-44.09%	-39.57%	8/7/2025 (Estimated)

Latest KURA, DNLI, BLTE, and CGON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million
3/25/2025	Q4 2024	CGON CG Oncology	-$0.37	-$0.48	-$0.11	-$0.48	$0.11 million	$0.46 million
3/17/2025	Q4 2024	BLTE Belite Bio	-$0.30	-$0.32	-$0.02	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	30.73	30.73
CGON CG Oncology	N/A	35.32	35.32
DNLI Denali Therapeutics	N/A	9.98	9.98
KURA Kura Oncology	0.02	11.47	11.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
CGON CG Oncology	26.56%
DNLI Denali Therapeutics	92.92%
KURA Kura Oncology	N/A

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
CGON CG Oncology	7.40%
DNLI Denali Therapeutics	12.50%
KURA Kura Oncology	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
CGON CG Oncology	61	76.23 million	N/A	Optionable
DNLI Denali Therapeutics	430	145.28 million	132.55 million	Optionable
KURA Kura Oncology	130	86.58 million	73.49 million	Optionable

KURA, DNLI, BLTE, and CGON Headlines

Recent News About These Companies

Kura Oncology (NASDAQ:KURA) Shares Gap Up - What's Next?

June 3 at 12:18 PM | marketbeat.com

ASCO25: Kura’s Phase II ziftomenib results trigger NDA acceptance from FDA

June 3 at 10:19 AM | finance.yahoo.com

ASCO: Kura, Kyowa reveal 23% remission rate behind oral leukemia drug's phase 2 win

June 2 at 7:07 PM | fiercebiotech.com

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

June 2 at 6:00 PM | globenewswire.com

FDA Grants Priority Review for Kura Oncology, Inc. (KURA) and Kyowa Kirin’s Ziftomenib

June 2 at 12:31 PM | insidermonkey.com

Squarepoint Ops LLC Takes $799,000 Position in Kura Oncology, Inc. (NASDAQ:KURA)

June 2 at 4:07 AM | marketbeat.com

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

June 1 at 7:00 PM | globenewswire.com

Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Price Target at $24.50

June 1 at 2:23 AM | americanbankingnews.com

Kura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by Two Sigma Advisers LP

May 30, 2025 | marketbeat.com

Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

May 30, 2025 | marketbeat.com

Kura Oncology at TD Cowen Summit: Strategic Innovations in Menin Inhibitors

May 29, 2025 | uk.investing.com

Cantor Fitzgerald maintains Overweight on Kura Oncology stock

May 26, 2025 | uk.investing.com

Kura Oncology (NASDAQ:KURA) Trading Down 4.7% - What's Next?

May 25, 2025 | marketbeat.com

Kura Oncology to present trial results for AML treatment

May 24, 2025 | investing.com

Rafferty Asset Management LLC Grows Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

May 24, 2025 | marketbeat.com

Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025

May 23, 2025 | insidermonkey.com

Millennium Management LLC Buys 1,521,954 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

May 23, 2025 | marketbeat.com

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

May 22, 2025 | globenewswire.com

Velan Capital Investment Management LP Buys Shares of 150,000 Kura Oncology, Inc. (NASDAQ:KURA)

May 21, 2025 | marketbeat.com

Kura Oncology, Inc. (NASDAQ:KURA) Stock Position Raised by BNP Paribas Financial Markets

May 21, 2025 | marketbeat.com

Kura Oncology, Inc. to Participate in Upcoming Investor Conferences in May and June 2025

May 20, 2025 | quiverquant.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA, DNLI, BLTE, and CGON Company Descriptions

Belite Bio NASDAQ:BLTE

$64.82 -0.20 (-0.31%)

Closing price 04:00 PM Eastern

Extended Trading

$64.76 -0.06 (-0.09%)

As of 08:00 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

CG Oncology NASDAQ:CGON

$26.79 +0.20 (+0.75%)

Closing price 04:00 PM Eastern

Extended Trading

$26.32 -0.47 (-1.75%)

As of 06:00 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Denali Therapeutics NASDAQ:DNLI

$13.93 -0.03 (-0.21%)

Closing price 04:00 PM Eastern

Extended Trading

$14.10 +0.17 (+1.22%)

As of 06:15 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Kura Oncology NASDAQ:KURA

$6.42 +0.12 (+1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$6.44 +0.02 (+0.30%)

As of 07:55 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time